Full metadata record
DC FieldValueLanguage
dc.contributorDepartment of Health Technology and Informaticsen_US
dc.contributor.advisorWong, Chi Ming (HTI)en_US
dc.creatorWu, Mengyao-
dc.publisherHong Kong Polytechnic Universityen_US
dc.rightsAll rights reserveden_US
dc.titleAmelioration of non-alcoholic fatty liver disease by targeting GPR110 in a diet-induced obese mouse modelen_US
dcterms.abstractRecent research has shown that the G protein-coupled receptor 110 (GPR110) is an oncogene evidenced by the increased expression of this receptor in numerous cancer types. Cell migration, invasion, and proliferation can all be reduced by GPR110 knockdown. GPR110 is, however, mostly expressed in the liver of healthy individuals. The precise physiological role of hepatic GPR110 in metabolism has not been revealed. In this study, I identified the unique role of GPR110 in association with the liver function in a mouse model of diet-induced obesity using a comprehensive metabolic phenotyping approach.en_US
dcterms.abstractThe expression of GPR110 in the liver was shown to be strictly regulated by nutritional availability using RT-qPCR and Western blot analyses. In both mice and humans, a high hepatic GPR110 level was strongly linked to the probability of developing liver steatosis. The disease severity of mice with non-alcoholic fatty liver disease (NAFLD) induced by a high-fat diet was alleviated when GPR110 was knocked down using antisense oligonucleotides. Stearoyl-coA desaturase 1 (SCD1), a crucial enzyme in hepatic de novo lipogenesis, has been identified as a downstream target of GPR110 by RNA-sequencing analysis. Treatment with the liver-specific SCD1 inhibitor MK8245 greatly improved the lipid profiles of GPR110-overexpressing mice and selective shRNAs against SCD1 in GPR110 infected primary hepatocytesen_US
dcterms.abstractIn my thesis work, I hereby provide the first evidence demonstrating that GPR110 plays a physiological role in regulating hepatic lipid metabolism through controlling the expression of SCD1. In obese individuals, down-regulation of GPR110 expression can potentially serve as a protective mechanism to stop the over-accumulation of lipids in the liver. My work has shed light on the future development of a rational therapeutic approach by inhibiting GPR110 for the management of NAFLD.en_US
dcterms.extentxxvi, 117 pages : color illustrationsen_US
dcterms.isPartOfPolyU Electronic Thesesen_US
dcterms.educationalLevelAll Doctorateen_US
dcterms.LCSHG proteins -- Receptorsen_US
dcterms.LCSHFatty liveren_US
dcterms.LCSHLiver -- Diseasesen_US
dcterms.LCSHHong Kong Polytechnic University -- Dissertationsen_US
dcterms.accessRightsopen accessen_US

Files in This Item:
File Description SizeFormat 
6723.pdfFor All Users2.27 MBAdobe PDFView/Open

Copyright Undertaking

As a bona fide Library user, I declare that:

  1. I will abide by the rules and legal ordinances governing copyright regarding the use of the Database.
  2. I will use the Database for the purpose of my research or private study only and not for circulation or further reproduction or any other purpose.
  3. I agree to indemnify and hold the University harmless from and against any loss, damage, cost, liability or expenses arising from copyright infringement or unauthorized usage.

By downloading any item(s) listed above, you acknowledge that you have read and understood the copyright undertaking as stated above, and agree to be bound by all of its terms.

Show simple item record

Please use this identifier to cite or link to this item: https://theses.lib.polyu.edu.hk/handle/200/12276